We’ve heard quite a bit about how advances in preventing and treating non-small cell lung cancer have moved the needle for cancer mortality in the U.S. One of the first immunotherapy agents to demonstrate improved survival compared to chemotherapy was nivolumab in the Checkmate 017 and 057 trials. Here we have 5-year outcomes from those trials. Despite the still limited prognosis, 5-year survival was more than 5 times as high with nivo (13.4%) than with chemo (2.6%). This report also demonstrates the impressive durability of a subset of immunotherapy responses. Patients who made it to the 2 year mark without progression had a >80% chance of surviving to 5 years and a >50% chance of remaining progression-free. TBL: The survival benefit of immunotherapy over chemotherapy is maintained long-term for patients with advanced NSCLC. | Borghael, J Clin Oncol 2021


  1. Hello! Some weeks ago I've got an essay from online paper writer free agency that are doing classy assignments and there is nothing to add. Even for my tutor of economics has nothing to add about the quality of their super professionalism. Perhaps economics is really an exciting subject for students?! Just have a look at this website if you would like to know more information.


Post a Comment

Popular Posts